Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity

Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity

Abstract Background The use of checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab) has revolutionised the treatment of metastatic melanoma. However still more than the half the patients do not respond to single-agent immunotherapy. This has led to the development of combining these agents i...

Full description

Bibliographic Details
Main Authors: Angus G. Dalgleish, Satvinder Mudan, Alberto Fusi
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Journal of Translational Medicine
Subjects:
Checkpoint blockade
Melanoma
IMM-101
Immunotherapy
Mycobacteria
Online Access:http://link.springer.com/article/10.1186/s12967-018-1602-8

Internet

http://link.springer.com/article/10.1186/s12967-018-1602-8

Similar Items